Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEX-22 (Nanexa AB)
- Development stage
- Unknown
- Lead developer
- Nanexa
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
NEX-22 is a once-monthly, long-acting injectable formulation of the GLP-1 receptor agonist liraglutide, developed by Nanexa AB for the treatment of type 2 diabetes. It utilizes Nanexa's proprietary PharmaShell® technology, which employs atomic layer deposition (ALD) to create a thin, inorganic coating around drug particles, enabling a controlled-release depot. This formulation is designed to improve patient adherence and reduce treatment discontinuation by extending the dosing interval from daily (as required by standard liraglutide products like Victoza) to once monthly. In Phase I clinical trials, NEX-22 demonstrated a sustained release profile over 36 days with dose linearity and a favorable safety profile, notably showing fewer gastrointestinal side effects compared to immediate-release GLP-1 agonists.
- Other names
- liraglutide PharmaShelllong-acting liraglutide
02
Targets
Beyond the preview
Go deeper on NEX-22 (Nanexa AB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEX-22 (Nanexa AB).